Compare AbbVie Inc (ABBV) vs Byrna Technologies Inc (BYRN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Byrna Technologies Inc — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while Byrna Technologies Inc trades at $5.97 (market cap $139.06M). The key difference: AbbVie Inc is far larger — about 3235.4× Byrna Technologies Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Byrna Technologies Inc pays none. Which is the better fit depends on your goals.
| ABBV | BYRN | |
|---|---|---|
Market Cap | $449.91B | $139.06M |
Sector | Health | Technology |
52-Week High | $261.07 | $32.30 |
52-Week Low | $184.85 | $4.96 |
Enterprise Value | $513.38B | $132.03M |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
BYRN trades at $7.08, up 1.58% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $16.75. The company reported Q4 2025 EPS beat but a Q1 2026 miss, with revenue of $118.12M in 2025 and a net income margin of 7.3%. Recent news highlights strategic marketing expansions and upcoming Q2 2026 earnings.
Outlook is cautiously optimistic given strong analyst buy ratings (71.4%) and a high price target upside, though risks include negative cash flow, ongoing legal investigations, and margin pressure from retail channel shifts. Earnings growth and successful execution of new initiatives are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →
